A CROI 2020 roundup of studies on birth control and women living with HIV.
New data shows the drug is not more likely to cause birth defects.
While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.
Jan. 23, 2020: Neurocognitive benefits of cannabis use; how unquantifiable HIV in CSF correlates to executive function; updated findings on efavirenz and microcephaly; cost-efficacy of a specialized HIV care coordination team.
While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.
A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.
Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.
The ECHO trial faces backlash and criticism.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.